Clinical Studies

Human clinical studies are woefully lacking for this substance, and need to be conducted to better elucidate its effects in humans, as well as to determine optimal dosing. Animal and in vitro studies suggest it is useful for many inflammatory and bronchoconstrictive conditions. Leukotrienes are suggested to play a role in the inflammatory process of ulcerative colitis. Boswellia extract (350 mg three times daily) was compared to sulfasalazine (1 g three times daily) in ulcerative colitis patients. Patients on the Boswellia extract showed similar improvements as patients on sulfasalazine, although 82 percent of Boswellia patients went into remission, compared with 75 percent on sulfasalazine.17